Jafron Biomedical announced that net income in the first half of the year is expected to be between 527 million yuan and 583 million yuan, a year-on-year increase of 90% to 110%. The growth in performance is mainly due to the improvement of external policy environment. The company has significant technological and market advantages in the field of blood perfusion, and its businesses such as kidney disease, liver disease, and critical illness have developed well. Revenue has grown year-on-year, unit production costs have decreased, and expenses have decreased.
健帆生物：预计上半年净利润同比增长90%至110%
Jafron Biomedical: Net income is expected to increase by 90%-110% year on year in the first half of the year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.